Market closed
Heron Therapeutics/$HRTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Heron Therapeutics
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
Ticker
$HRTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
126
Website
HRTX Metrics
BasicAdvanced
$254M
-
-$0.18
1.81
-
Price and volume
Market cap
$254M
Beta
1.81
52-week high
$3.93
52-week low
$1.04
Average daily volume
1.7M
Financial strength
Current ratio
2.282
Quick ratio
1.612
Long term debt to equity
-437.438
Total debt to equity
-445.559
Interest coverage (TTM)
-1.27%
Management effectiveness
Return on assets (TTM)
-2.31%
Return on equity (TTM)
82.51%
Valuation
Price to revenue (TTM)
1.843
Price to book
-6.33
Price to tangible book (TTM)
-6.33
Price to free cash flow (TTM)
-26.406
Growth
Revenue change (TTM)
12.13%
Earnings per share change (TTM)
-80.00%
3-year revenue growth (CAGR)
16.87%
3-year earnings per share growth (CAGR)
-57.45%
What the Analysts think about HRTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Heron Therapeutics stock.
HRTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HRTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HRTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Heron Therapeutics stock?
Heron Therapeutics (HRTX) has a market cap of $254M as of January 31, 2025.
What is the P/E ratio for Heron Therapeutics stock?
The price to earnings (P/E) ratio for Heron Therapeutics (HRTX) stock is 0 as of January 31, 2025.
Does Heron Therapeutics stock pay dividends?
No, Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Heron Therapeutics dividend payment date?
Heron Therapeutics (HRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Heron Therapeutics?
Heron Therapeutics (HRTX) has a beta rating of 1.81. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.